Brought to you by 
Teva and AbCellera agree to collaborate for monoclonal antibodies
13 Jun 2017
Executive Summary
Teva Pharmaceutical Industries Ltd. and AbCellera Biologics Inc. have entered into a collaborative research agreement in which AbCellera will apply its high-throughput single cell antibody platform for the discovery of monoclonal antibodies. The company recently entered into another antibody discovery collaboration with Merck to generate antibodies against an undisclosed target.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Concluded
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Teva and AbCellera agree to collaborate for monoclonal antibodies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice